Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours.

Boller D, Doepfner KT, De Laurentiis A, Guerreiro AS, Marinov M, Shalaby T, Depledge P, Robson A, Saghir N, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Fattet S, Delattre O, Schweri-Olac A, Höland K, Grotzer MA, Frei K, Spertini O, Waterfield MD, Arcaro A.

Anticancer Res. 2012 Aug;32(8):3015-27.

PMID:
22843869
2.

Major role of epidermal growth factor receptor and Src kinases in promoting oxidative stress-dependent loss of adhesion and apoptosis in epithelial cells.

Chan HL, Chou HC, Duran M, Gruenewald J, Waterfield MD, Ridley A, Timms JF.

J Biol Chem. 2010 Feb 12;285(7):4307-18. doi: 10.1074/jbc.M109.047027. Epub 2009 Dec 7.

3.

Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors.

Zvelebil MJ, Waterfield MD, Shuttleworth SJ.

Arch Biochem Biophys. 2008 Sep 15;477(2):404-10. doi: 10.1016/j.abb.2008.06.024. Epub 2008 Jul 8.

PMID:
18647592
4.

A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding.

Jefferies HB, Cooke FT, Jat P, Boucheron C, Koizumi T, Hayakawa M, Kaizawa H, Ohishi T, Workman P, Waterfield MD, Parker PJ.

EMBO Rep. 2008 Feb;9(2):164-70. doi: 10.1038/sj.embor.7401155. Epub 2008 Jan 11.

5.

Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.

Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P, Waterfield MD.

Bioorg Med Chem. 2007 Sep 1;15(17):5837-44. Epub 2007 Jun 6.

PMID:
17601739
6.

Dynamic cofilin phosphorylation in the control of lamellipodial actin homeostasis.

Jovceva E, Larsen MR, Waterfield MD, Baum B, Timms JF.

J Cell Sci. 2007 Jun 1;120(Pt 11):1888-97. Epub 2007 May 15.

7.

Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.

Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Workman P, Waterfield MD, Parker P.

Bioorg Med Chem Lett. 2007 May 1;17(9):2438-42. Epub 2007 Feb 15.

PMID:
17339109
8.

Exploring the specificity of the PI3K family inhibitor LY294002.

Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD.

Biochem J. 2007 May 15;404(1):15-21.

9.

Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors.

Hayakawa M, Kaizawa H, Kawaguchi K, Ishikawa N, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Waterfield MD, Parker P, Workman P.

Bioorg Med Chem. 2007 Jan 1;15(1):403-12. Epub 2006 Oct 16.

PMID:
17049248
10.

Structural and membrane binding analysis of the Phox homology domain of phosphoinositide 3-kinase-C2alpha.

Stahelin RV, Karathanassis D, Bruzik KS, Waterfield MD, Bravo J, Williams RL, Cho W.

J Biol Chem. 2006 Dec 22;281(51):39396-406. Epub 2006 Oct 12.

11.

Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms.

Katso RM, Pardo OE, Palamidessi A, Franz CM, Marinov M, De Laurentiis A, Downward J, Scita G, Ridley AJ, Waterfield MD, Arcaro A.

Mol Biol Cell. 2006 Sep;17(9):3729-44. Epub 2006 Jun 14.

12.

Proteomic analysis of UVC irradiation-induced damage of plasma proteins: Serum amyloid P component as a major target of photolysis.

Chan HL, Gaffney PR, Waterfield MD, Anderle H, Peter Matthiessen H, Schwarz HP, Turecek PL, Timms JF.

FEBS Lett. 2006 May 29;580(13):3229-36. Epub 2006 May 6.

13.

A parallel proteomic and metabolomic analysis of the hydrogen peroxide- and Sty1p-dependent stress response in Schizosaccharomyces pombe.

Weeks ME, Sinclair J, Butt A, Chung YL, Worthington JL, Wilkinson CR, Griffiths J, Jones N, Waterfield MD, Timms JF.

Proteomics. 2006 May;6(9):2772-96.

PMID:
16548067
14.
15.
16.

Stress-induced changes in the Schizosaccharomyces pombe proteome using two-dimensional difference gel electrophoresis, mass spectrometry and a novel integrated robotics platform.

Weeks ME, Sinclair J, Jacob RJ, Saxton MJ, Kirby S, Jones J, Waterfield MD, Cramer R, Timms JF.

Proteomics. 2005 Apr;5(6):1669-85.

PMID:
15789347
17.

Gene targeting: attention to detail.

Vanhaesebroeck B, Rohn JL, Waterfield MD.

Cell. 2004 Aug 6;118(3):274-6.

18.

The urinary proteome in Fanconi syndrome implies specificity in the reabsorption of proteins by renal proximal tubule cells.

Cutillas PR, Chalkley RJ, Hansen KC, Cramer R, Norden AG, Waterfield MD, Burlingame AL, Unwin RJ.

Am J Physiol Renal Physiol. 2004 Sep;287(3):F353-64. Epub 2004 May 12.

19.

Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression.

White SL, Gharbi S, Bertani MF, Chan HL, Waterfield MD, Timms JF.

Br J Cancer. 2004 Jan 12;90(1):173-81.

21.

Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation.

Arcaro A, Khanzada UK, Vanhaesebroeck B, Tetley TD, Waterfield MD, Seckl MJ.

EMBO J. 2002 Oct 1;21(19):5097-108.

22.

Factors governing the solubilization of phosphopeptides retained on ferric NTA IMAC beads and their analysis by MALDI TOFMS.

Hart SR, Waterfield MD, Burlingame AL, Cramer R.

J Am Soc Mass Spectrom. 2002 Sep;13(9):1042-51.

PMID:
12322952
23.
24.

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.

Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD, Smith AJ, Vanhaesebroeck B.

Science. 2002 Aug 9;297(5583):1031-4. Epub 2002 Jul 18.

25.

Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system.

Gharbi S, Gaffney P, Yang A, Zvelebil MJ, Cramer R, Waterfield MD, Timms JF.

Mol Cell Proteomics. 2002 Feb;1(2):91-8.

26.

Differential proteome analysis of replicative senescence in rat embryo fibroblasts.

Benvenuti S, Cramer R, Quinn CC, Bruce J, Zvelebil M, Corless S, Bond J, Yang A, Hockfield S, Burlingame AL, Waterfield MD, Jat PS.

Mol Cell Proteomics. 2002 Apr;1(4):280-92.

27.

Identification of novel candidates for replicative senescence by functional proteomics.

Benvenuti S, Cramer R, Bruce J, Waterfield MD, Jat PS.

Oncogene. 2002 Jun 27;21(28):4403-13. Erratum in: Oncogene 2002 Oct 24;21(49):7609.

28.

Cluster analysis of an extensive human breast cancer cell line protein expression map database.

Harris RA, Yang A, Stein RC, Lucy K, Brusten L, Herath A, Parekh R, Waterfield MD, O'Hare MJ, Neville MA, Page MJ, Zvelebil MJ.

Proteomics. 2002 Feb;2(2):212-23.

PMID:
11840567
29.

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD.

Annu Rev Cell Dev Biol. 2001;17:615-75. Review.

PMID:
11687500
30.

Proteomics--post-genomic cartography to understand gene function.

Naaby-Hansen S, Waterfield MD, Cramer R.

Trends Pharmacol Sci. 2001 Jul;22(7):376-84. Review.

PMID:
11431033
31.

Synthesis and function of 3-phosphorylated inositol lipids.

Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD.

Annu Rev Biochem. 2001;70:535-602. Review.

PMID:
11395417
32.

Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.

Pirola L, Zvelebil MJ, Bulgarelli-Leva G, Van Obberghen E, Waterfield MD, Wymann MP.

J Biol Chem. 2001 Jun 15;276(24):21544-54. Epub 2001 Feb 13.

33.

Beta1-integrin and PTEN control the phosphorylation of protein kinase C.

Parekh DB, Katso RM, Leslie NR, Downes CP, Procyk KJ, Waterfield MD, Parker PJ.

Biochem J. 2000 Dec 1;352 Pt 2:425-33.

34.

PI3-kinase inhibition: a target for drug development?

Stein RC, Waterfield MD.

Mol Med Today. 2000 Sep;6(9):347-57. Review.

PMID:
10954868
35.

Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors.

Arcaro A, Zvelebil MJ, Wallasch C, Ullrich A, Waterfield MD, Domin J.

Mol Cell Biol. 2000 Jun;20(11):3817-30.

36.

The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles.

Domin J, Gaidarov I, Smith ME, Keen JH, Waterfield MD.

J Biol Chem. 2000 Apr 21;275(16):11943-50.

37.

Alternative modes of binding of proteins with tandem SH2 domains.

O'Brien R, Rugman P, Renzoni D, Layton M, Handa R, Hilyard K, Waterfield MD, Driscoll PC, Ladbury JE.

Protein Sci. 2000 Mar;9(3):570-9.

38.

Signaling by distinct classes of phosphoinositide 3-kinases.

Vanhaesebroeck B, Waterfield MD.

Exp Cell Res. 1999 Nov 25;253(1):239-54. Review.

PMID:
10579926
39.

The SH3 and BH domains of the p85alpha adapter subunit play a critical role in regulating class Ia phosphoinositide 3-kinase function.

Beeton CA, Das P, Waterfield MD, Shepherd PR.

Mol Cell Biol Res Commun. 1999 May;1(2):153-7.

PMID:
10356365
40.

Phosphatidylinositol-3-OH kinases are Rab5 effectors.

Christoforidis S, Miaczynska M, Ashman K, Wilm M, Zhao L, Yip SC, Waterfield MD, Backer JM, Zerial M.

Nat Cell Biol. 1999 Aug;1(4):249-52. No abstract available.

PMID:
10559924
41.

Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages.

Vanhaesebroeck B, Jones GE, Allen WE, Zicha D, Hooshmand-Rad R, Sawyer C, Wells C, Waterfield MD, Ridley AJ.

Nat Cell Biol. 1999 May;1(1):69-71. No abstract available.

PMID:
10559867
42.

Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties.

Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC, O'Hare MJ.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12589-94.

43.

Regulation of imaginal disc cell size, cell number and organ size by Drosophila class I(A) phosphoinositide 3-kinase and its adaptor.

Weinkove D, Neufeld TP, Twardzik T, Waterfield MD, Leevers SJ.

Curr Biol. 1999 Sep 23;9(18):1019-29. Erratum in: Curr Biol 1999 Nov 18;9(22):R867.

44.

Structural and biochemical evaluation of the interaction of the phosphatidylinositol 3-kinase p85alpha Src homology 2 domains with phosphoinositides and inositol polyphosphates.

Surdo PL, Bottomley MJ, Arcaro A, Siegal G, Panayotou G, Sankar A, Gaffney PR, Riley AM, Potter BV, Waterfield MD, Driscoll PC.

J Biol Chem. 1999 May 28;274(22):15678-85.

45.

Insulin activates the alpha isoform of class II phosphoinositide 3-kinase.

Brown RA, Domin J, Arcaro A, Waterfield MD, Shepherd PR.

J Biol Chem. 1999 May 21;274(21):14529-32.

46.

Intermolecular interactions of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase.

Harpur AG, Layton MJ, Das P, Bottomley MJ, Panayotou G, Driscoll PC, Waterfield MD.

J Biol Chem. 1999 Apr 30;274(18):12323-32.

47.

Signalling through phosphoinositide 3-kinases: the lipids take centre stage.

Leevers SJ, Vanhaesebroeck B, Waterfield MD.

Curr Opin Cell Biol. 1999 Apr;11(2):219-25. Review.

PMID:
10209156
48.

Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo.

Vanhaesebroeck B, Higashi K, Raven C, Welham M, Anderson S, Brennan P, Ward SG, Waterfield MD.

EMBO J. 1999 Mar 1;18(5):1292-302.

49.
50.

Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity.

Arcaro A, Volinia S, Zvelebil MJ, Stein R, Watton SJ, Layton MJ, Gout I, Ahmadi K, Downward J, Waterfield MD.

J Biol Chem. 1998 Dec 4;273(49):33082-90.

Supplemental Content

Loading ...
Support Center